Center Outcomes Forum - 2023
October 18, 2023
CIBMTR Funding Disclosure: - Rizzo

CIBMTR receives financial support from the government, foundations and industry entities listed below to support broad research and educational missions. These funding sources are disclosed for transparency. Scientific and administrative review processes prevent direct influence of the funding sources to the CIBMTR scientific research agenda and individual research products and findings.

The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); U24HL138660 and U24HL157560 from NHLBI and NCI; U24CA233032 from the NCI; OT3HL147741 from the NHLBI; HHS25020170006C, 75R60222C00008 and 75R60222C00009 from the Health Resources and Services Administration (HRSA); and N00014-21-1-2954 and N00014-23-1-2057 from the Office of Naval Research; Additional federal support is provided by P01CA111412, R01CA100019, R01CA152108, R01CA218285, R01CA231141, R01CA231838, R01CA262899, R01AI128775, R01AI150999, R01AI158861, R01HL155741, R01HL131731, UM1CA121947, U01AI069197, U01AI126612, UG1HL069254. Support is also provided by Be the Match Foundation; Boston Children's Hospital; Dana Farber; St. Baldrick’s Foundation; PBMTF; Stanford University; Medical College of Wisconsin; National Marrow Donor Program; and from the following commercial entities: AbbVie; Actinium Pharmaceuticals, Inc.; Adaptimmune; Adaptive Biotechnologies Corporation; ADC Therapeutics; Adienne SA; Allogene; AlloVir, Inc.; Amgen, Inc.; Angiocrine; Anthem; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics; BeiGene; bluebird bio, inc.; Bristol Myers Squibb Co.; CareDx Inc.; CRISPR; CSL Behring; CytoSen Therapeutics, Inc.; Eurofins Viracor, DBA Eurofins Transplant Diagnostics; Gamida-Cell, Ltd.; Gilead; GlaxoSmithKline; HistoGenetics; Incyte Corporation; Iovance; Janssen Research & Development, LLC; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Kadmon; Karius; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Mallinckrodt Pharmaceuticals; Medexus Pharma; Merck & Co.; Mesoblast; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; MorphoSys; Novartis Pharmaceuticals Corporation; Omeros Corporation; OptumHealth; Orca Biosystems, Inc.; Ossium Health, Inc.; Pfizer, Inc.; Pharmacies, LLC, An AbbVie Company; Pluristem; PPD Development, LP; Sanofi; Sanofi-Aventis U.S. Inc.; Sobi, Inc.; Stemcyte; Takeda Pharmaceuticals; Talaris Therapeutics; Terumo Blood and Cell Technologies; TG Therapeutics; Vertex Pharmaceuticals; Vor Biopharma Inc.; Xenikos BV. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government.
Agenda – COF 2023

• Purpose
• Agenda Overview
  – Center-Specific Survival Analysis 2023 Summary
  – Research presentations
  – Workgroup presentations and DISCUSSION
• Communication Plans
• Next steps/Wrap Up
My sincere appreciation

• Center-Specific Analysis “Core” Team:
  – Charimar Santiago-Parrilla, Michael Heim, Molly Allbee-Johnson, Waleska Perez, Sue Logan, Jenni Bloomquist, Eileen Tuschl, Laura Clements, Steve Spellman, Brent Logan, Kwang Ahn, Kristin Page

• Carol Doleysh – Program Manager, SCTOD

• Alicia Halfmann and Carol – Center Outcomes Forum

• Workgroups and presenters:
  – Akshay Sharma, Christopher Strouse, Wael Saber
  – WG leaders: Chris Dandoy, Kristin Page, Mike Verneris
  – WG panelists – See Appendix
C.W. Bill Young Cell Transplantation Program*

US Department of Health and Human Services
Health Resources and Services Administration
Healthcare Systems Bureau / Division of Transplantation

Advisory Council on Blood Stem Cell Transplantation

National Cord Blood Inventory (NCBI)
Stem Cell Therapeutic Outcomes Database (SCTOD)
Single Point of Access–Coordinating Center (SPA-CC)
Office of Patient Advocacy (OPA)

Individually contracted and accredited cord blood banks

Components of the C. W. Bill Young Cell Transplantation Program

Transplant centers, patients and families, referring physicians

* Established by the Stem Cell Therapeutic and Research Act of 2005 and reauthorized by the Stem Cell Therapeutic and Research Reauthorization Acts of 2010 and 2015 and the TRANSPLANT Act of 2021
Center-Specific Survival Analysis 2023
Center Outcomes Report
Final study population - 2023

- Center outcomes report 2023 includes 3 full years of data:
  - Unrelated and Related HCT 2019 – 2021
- Multivariate analysis adjusts for ‘risk factors’
- Centers must have >90% overall f/u at 1 year
- 178 US centers; 25,532 patients first allogeneic HCT
  - 4 centers (~553 pts) removed because of quality concerns in audits
- Primary outcome: One-year survival
  - Overall: 76.2% (78.1% REL, 74.6% UNR) – 2021: 76.5, 78.3, 75.1
How are US centers doing? 2023

Risk Adjusted Performance

- 86% As Expected
- 7% Above Expected
- 7% Below Expected

N = 175
What else did we test in the 2023 Report

- COVID Infection pre-HCT
- Previous Solid Organ Tx
- Distinct disease category for BM Failure syndrome
- Updated AML ELN 2022
- Time from dx to tx for AML PIF
- Updated ALL cytogenetic /molecular risk stratification
- MRD for AML and ALL
- Updated other acute leukemia categories and dz status
- Updated MM cytogenetic risk
- R-ISS for MM
What was changed in the 2023 Report

• Additions:
  – Previous Solid Organ Tx
  – Distinct Disease category for BM Failure syndrome
  – AML ELN 2022
  – ALL cytogenetic/molecular risk stratification
  – Updated “other acute leukemia” categories and dz status

• No change or removed:
  – MRD for AML and ALL
  – Updated MM cytogenetic risk
  – R-ISS for MM
  – Therapy-related AML and MDS
What are our plans for 2024 Analysis?

• Re-assess MRD for AML, ALL based on best available existing data
• Test new variables based on COF 2018/2020 recommendations for:
  – Hemoglobinopathies – TRJB, LIC, RBC dependence, iron chelation
  – Immune system disorders – active/recent viral infection, ever PJP
  – Histiocytic disorders - active/recent viral infection, ever PJP
• Test new variables for pediatric pts – Peds GFR, Cong heart disease
What are our plans for 2024 Analysis?

• Test serum ferritin, albumin, plt at transplant, poverty, prior cell therapy
• Incorporate, where possible, ideas brought forward from this Center Outcomes Forum
What else are we doing? - Research

• SC 21-02 (Sharma A, et al)
  – Impact of Center Specific Analysis scores on Hematopoietic Cell Transplant Center Volumes
  – Transplant Cellular Therapy 2023 Aug;29(8) 523-528.

• SC 21-01 (Strouse C, et al)
  – Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for HCT.
  – ASH 2023 oral abstract
I. Key Questions for the workgroup to address:
   a. What revisions should CIBMTR consider making to current processes to collect recommendations about data (especially disease-specific) to be used in risk adjustment for the center specific survival analysis? This is essential to maintain up-to-date and relevant risk adjustment.
   b. What (if any) additional approaches to communication should be made by CIBMTR to inform relevant stakeholders about the center specific survival analysis and ongoing changes to risk adjustment?
I. Key Questions for the workgroup to address:
   a. What additional information already collected by the CIBMTR should be used for disease-based risk adjustment for AML, ALL, and MDS?
   b. Should CIBMTR begin to use MRD as a risk adjustment in AML and ALL, and if so, what criteria should be used to define MRD?
   c. What changes in data collection are recommended soon to improve risk adjustment for AML, ALL, and MDS while being respectful of practical issues related to data collection at centers?
Workgroup 3 Charter

I. Key Questions for the workgroup to address:
   a. Should CIBMTR collect specific information about patients’ participation in transplant-related clinical trials to inform future analyses about the impact of trials-based care on clinical outcomes?
   b. What specific types of information should be collected by CIBMTR for this objective? What barriers must be overcome?
      i. Phase of trial development?
      ii. Type of intervention (eg directly related to transplant procedure (prep regimen, graft source/manipulation, gvhd prophylaxis), supportive care, treatment of early complications, or other)?
      iii. Identify discrete, unambiguous, and readily available data that can be provided by centers to achieve this objective.
   c. Beyond traditional patient-, disease-, and transplant- characteristics, should CIBMTR test information related to clinical trials participation for inclusion in future center specific risk adjustment model?
      i. Are there potential negative consequences that can be anticipated?
The CIBMTR® (Center for International Blood and Marrow Transplant Research®) is a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin (MCW).

Thank you